ACS Medicinal Chemistry Letters

Letter

Subscriber access provided by TULANE UNIVERSITY

Investigation around the oxadiazole core in the discovery of a new chemotype of potent and selective FXR antagonists

Carmen Festa, Claudia Finamore, Silvia Marchianò, Francesco Saverio Di Leva, Adriana Carino, Maria Chiara Monti, Federica del Gaudio, Sara Ceccacci, Vittorio Limongelli, Angela Zampella, Stefano Fiorucci, and Simona De Marino

ACS Med. Chem. Lett., Just Accepted Manuscript • DOI: 10.1021/acsmedchemlett.8b00534 • Publication Date (Web): 10 Jan 2019 Downloaded from http://pubs.acs.org on January 12, 2019

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

7

8 9 10

11

12

13

14

15

16

17

18 19

20 21

22

23

24

25

26 27 28

29

30

31

32

33

34

35

58 59

60

Investigation around the oxadiazole core in the discovery of a new chemotype of potent and selective FXR antagonists

Carmen Festa,¹ Claudia Finamore,¹ Silvia Marchianò,² Francesco Saverio Di Leva¹, Adriana Carino,² Maria Chiara Monti,⁴ Federica del Gaudio,⁴ Sara Ceccacci,⁴ Vittorio Limongelli,^{1,3} Angela Zampella,¹ Stefano Fiorucci² and Simona De Marino^{1*}

¹Department of Pharmacy, University of Naples "Federico II", Via D. Montesano 49, 80131 Naples, Italy.

²Department of Surgery and Biomedical Sciences, Nuova Facoltà di Medicina, Perugia, Italy.

³Università della Svizzera Italiana (USI), Faculty of Biomedical Sciences, Institute of Computational Science - Center for Computational Medicine in Cardiology, Via G. Buffi 13, CH-6900 Lugano, Switzerland.

⁴Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 132, 84084, Fisciano, Salerno, Italy.

KEYWORDS: FXR antagonists, bile acid receptor, 1,2,4-oxadiazole core, piperidine ring and pyrrolidine ring

ABSTRACT: Recent findings have shown that FXR antagonists might be useful in the treatment of cholestasis and related metabolic disorders. In this paper we report the discovery of a new chemotype of FXR antagonists featured by a 3,5-disubstituted oxadiazole core. In total, 35 new derivatives were designed and synthesized and notably, compounds **3f** and **13**, containing a piperidine ring, displayed the best antagonistic activity against FXR with promising cellular potency ($IC_{50}=0.58\pm0.27 \mu M$ and $0.127\pm0.02 \mu M$, respectively). The excellent pharmacokinetic properties make compound **3f** as the most promising lead identified in this study.

Farnesoid X Receptor (FXR, also known as BAR, NR1H4), a ligand-dependent transcription factor, belongs to the super-family of metabolic nuclear receptors. FXR is highly expressed in the liver, intestine, kidney, and adrenals, and it responds to bile acids¹ regulating their homeostasis and governing lipid and glucose metabolism in the liver.²⁻⁶ For all these reasons, FXR represents a promising pharmacological target in the management of metabolic disorders.

36 The most potent endogenous ligand of FXR is chenodeoxycholic 37 acid (CDCA), a primary bile acid found in human bile. FXR 38 agonists bind to the FXR's ligand-binding activation function 2 39 (AF-2) domain (LBD) inducing a receptor conformational change responsible for the release of co-repressor molecules (such as N-40 Cor) and the recruitment of co-activators (such as SRC-1). The 41 FXR/co-activator complex assisted by the RXR protein binds to 42 specific regions of DNA enhancing the expression of target genes. 43 On the other hand, the binding of an antagonist molecule to the 44 FXR LBD induces a shift of AF-2 helix which assumes an 45 orientation unable to recruit the co-activators, thus leading to 46 transcriptional silencing.7

The strong interest towards FXR agonists is linked to the ability
of these compounds in regulating bile acid homeostasis in
cholestasis, lowering plasma lipogenesis, repressing very low
density lipoprotein production, increasing plasma triglyceride
clearance, improving insulin sensitivity, and promoting the
storage of glycogen.^{8,9}

In recent years, several FXR agonists, belonging to steroidal and
non-steroidal scaffolds, have been identified as potential leads for
the treatment of metabolic disorders with some of them progressed
advanced clinical trials for the treatment of patients with
primary biliary cirrhosis (PBC) and non-alcoholic steatohepatitis

(NASH).¹⁰ Unfortunately, the side effects resulted from the phase III clinical trials of 6-ECDCA, the most promising steroidal FXR agonist,¹⁰ raised concerns about the use of FXR agonists in the treatment of metabolic liver diseases. In addition, the recent finding that the FXR gene ablation protects from liver injury caused by bile duct ligation (BDL), has moved the attention towards the FXR antagonism in the treatment of obstructive cholestasis.¹¹

As in the case of the agonists, both steroidal and non-steroidal compounds¹²⁻¹⁴ have been identified as FXR antagonists. Among the steroidal scaffolds, the most promising are natural compounds with glyco-\beta-muricholic acid (GBMCA) currently in advanced pre-clinical trials for the treatment of obesity, NAFLD, and insulin resistance.15 In this work, starting from the recent discovery of Flesch et al.¹⁶ who showed that structural fragmentation on GW4064, a highly potent and selective non-steroidal FXR agonist, can lead to the shift of the receptor modulation from the agonism to the antagonism, we aimed at developing novel non-steroidal FXR antagonists. In particular, Flesch et al.¹⁶ reported that the removal of the bulky 4-substituent from the isoxazole ring of GW4064 can be a valuable starting point for the synthesis of FXR antagonists. In detail, the replacement of the isoxazole ring in GW4064 with a 3,5-disubsituted oxadiazole led to compounds with different activity profiles, from agonism, partial agonism to antagonism.

The 1,2,4-oxadiazole ring is interesting from the chemical synthesis point of view, being an accessible and highly diversifiable scaffold that can be exploited to improve the pharmacokinetics, pharmacodynamics and the selectivity profile of the drug candidates.

This is the case of compound **1** in Figure 1, a highly simplified GW4064 derivative endowed with an antagonistic profile toward FXR.

Figure 1

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40 41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58 59

60



Despite the promising pharmacological profile of 1, a strong rationale of its activity, supported by the elucidation of the ligand binding mode, is lacking. Therefore, we have decided to explore further this scaffold, modifying both substituents at C-3 and C-5 of the oxadiazole moiety developing a small library of derivatives listed in Table 1. In particular, the lipophilic *p*-methoxyphenyl at C-5 in 1 was replaced by different protonable N-bearing heterocyclic substituents, such as a piperidine or a pyrrolidine ring. It is worth noting that a similar substituent has been recently reported by Teno et al,13 in a new chemotype of FXR antagonists with the evidence that the replacement of a cyclohexyl component with a ionizable piperidine ring increases the binding activity to FXR. The research of Teno et al. led finally to the identification of N-acylated electrically neutral potent FXR antagonists. At variance with the Teno's compounds, in our derivatives the Nbearing ring is not acetylated, hence protonable, thus endowing basic properties to our compounds and allowing to explore the piperidine moiety as available H-bond donor group in the FXR-LBD.

Here we report the pharmacological evaluation, the assessment of the *in vitro* pharmacokinetic properties and the ligand binding mode to FXR of the newly synthesized compounds that allowed the identification of novel potent FXR antagonists with promising pharmacokinetic properties.

The structure of the synthesized compounds was confirmed by spectroscopic and analytical techniques and the structural characterization is available in the SI.

Synthesis started with oxadiazole derivatives **3a-f** prepared from the nitriles **1a-1f** and *N*-Boc-isonipecotic acid (*N*-Boc-Inp-OH), as starting materials (Scheme 1).

Scheme 1. General synthetic procedure to prepare 1,2,4oxadiazole derivatives 3a-f^a



^{*a}Reagents and conditions*: a) NH₂OH HCl, K₂CO₃ in CH₃OH, reflux, 100-90% yield; b) *N*-Boc-Inp-OH, DIPEA, HBTU in DMF dry, 80 °C, 60-80% yield; c) TFA:CH₂Cl₂ 1:1, 2 h, quantitative yield.</sup>

Briefly, treatment of nitriles **1a-f** with hydroxylamine hydrochloride afforded the intermediate amidoximes **2a-f** in quantitative yield.

Reaction with N-Boc-isonipecotic acid (N-Boc-Inp-OH), using HBTU as coupling agent, followed by deprotection of the Boc protecting group in acidic conditions, led to compounds 3a-f (Scheme 1). Compounds 3a-f were evaluated in a luciferase reporter assay on HepG2 cells transiently transfected with human FXR (Table 1). None of the above compounds resulted able to transactivate FXR in agonistic mode at 10 µM concentration (Figure S3) whereas cell co-stimulation in presence of CDCA $(10 \,\mu\text{M})$ reveals that, among this series, derivative 3f was relatively effective (80% antagonistic rate) in inhibiting FXR activation caused by CDCA, and the above efficacy data was accompanied by a promising potency (IC₅₀ 0.58±0.27 µM). Having identified the 3-naphtyl-1,2,4-oxadiazole as a promising core in FXR antagonism, substitutions preserving the naphtyl at C-3 and the protonable core at C-5 have been explored. First, compounds 13 and 23 have been prepared reacting the amidoxima 2f with N-Boc-L-pipecolic acid (N-Boc-L-Pip-OH) and N-Boc-Lproline (N-Boc-L-Pro-OH) (Scheme 2), in order to explore the influence of different size and different position of the nitrogen in the heterocyclic moiety at C-5. Compound 13 was also demonstrated a high potent FXR antagonist (IC50 0.127±0.02 µM), whereas a dramatic loss of potency was observed for the corresponding proline derivative 23, thus identifying the Nbearing six membered heterocycle as a key structural element at C-5 position on the central 1,2,4-oxadiazole moiety. Then, the effect of the introduction of N-alkyl side chain with differentiated lengths and functionalization has been focused, using compounds **3f**, **13** and **23** as cornerstone intermediates. *N*-alkylation with β , γ or δ -bromo esters, as depicted in the Scheme 2, allowed the introduction of C-3/C-4 or C-5 side chains with the methyl ester end-group. Basic hydrolysis with LiOH and reduction with DIBAL-H afforded the corresponding acids and alcohols (Scheme 2).

Scheme 2. Synthesis of analogues 4-32



^a*Reagents and conditions* a) N-Boc-Inp-OH, DIPEA, HBTU in DMF, 80 °C, 80% yield; b) TFA:CH₂Cl₂ 1:1, 2 h, quantitative yield; c) N-Boc-L-Pip-OH, DIPEA, HBTU in DMF dry, 80 °C, 78% yield; d) N-Boc-L-Pro-OH, DIPEA, HBTU in DMF dry, 80 °C, 83% yield; e) methyl 3-bromopropanoate, methyl 4-bromobutanoate or methyl 5-bromopentanoate, DIPEA, in

CH₃CN dry, 60 °C, over night, 65-92% yield; f) LiOH in THF/H₂O (2:1), 0 °C then room temperature, 24 h, 40-60% vield; g) DIBAL-H (1 M in toluene) in THF dry, 0 °C, 48 h, 57-82% vield.

Alkylation at the nitrogen affects FXR antagonism. As shown in Table 1, the effects in term of efficacy/potency is highly dependent on the position of the nitrogen in the cycle, the length of the alkyl chain and the nature of the terminal functional group (COOH or CH₂OH). Foremost, the introduction of alkyl side chains bearing a carboxylic group produces substantial changes in FXR antagonistic activity compared to non-alkylated counterparts, with dramatic increase in IC₅₀ values. Importantly, the above loss in potency is independent by the length of the N-alkyl chain and by the position of the nitrogen on the heterocycle at C-5.

Of interest, the replacement of the carboxylic end group with a neutral alcoholic functional group preserves the antagonistic activity toward FXR. Furthermore, the biological activity indicates that the efficacy in antagonizing FXR correlates with the size of the installed side chain, with the best match found for the C-4 side chain as in compounds 9 and 19 (IC₅₀ value of 1.17 and 7.0 μ M, respectively). The comparison between the IC₅₀ values of the N-alkylated piperidine derivatives with those of the N-free piperidine 3f and 13, shows that the modification at the nitrogen atom alters the ligand potency, prompting the non-substituted piperidine ring as a key structural element in the FXR antagonism, with compounds **3f** and **13** the best hits identified in this study.

All the synthetized compounds showed no agonistic activity towards FXR (Figure S3).

Table 1. FXR antagonistic activity of substituted 1,2,4-oxadiazole derivatives

Compound	R	n		Y	Efficacy [%] ^a	IC ₅₀ ^b
3a		2	CH ₂	NH	0	-
3b	CF3	2	CH ₂	NH	44	-
3c	•	2	CH ₂	NH	9	-
3d	O CF3	2	CH ₂	NH	13	-
3e		2	CH ₂	NH	49	-
3f	Naph	2	CH ₂	NH	80	0.58±0.27 μM
5	Naph	2	CH ₂	N(CH ₂) ₂ COOH	19	-
6	Naph	2	CH ₂	N(CH ₂) ₂ CH ₂ OH	67	40.4±7.66 µM
8	Naph	2	CH ₂	N(CH ₂) ₃ COOH	74	25.7±1.69 µM
9	Naph	2	CH ₂	N(CH ₂) ₃ CH ₂ OH	95	1.17±0.41 µM
11	Naph	2	CH ₂	N(CH ₂) ₄ COOH	2	-
12	Naph	2	CH ₂	N(CH ₂) ₄ CH ₂ OH	48	-
13	Naph	2	NH	CH ₂	96	0.127±0.02 μM
15	Naph	2	N(CH ₂) ₂ COOH	CH ₂	17	-
16	Naph	2	N(CH ₂) ₂ CH ₂ OH	CH ₂	59	27.0±5.7 μM
18	Naph	2	N(CH ₂) ₃ COOH	CH ₂	40	-
19	Naph	2	N(CH ₂) ₃ CH ₂ OH	CH ₂	82	7.0±2.18 μM
21	Naph	2	N(CH ₂) ₄ COOH	CH ₂	49	-
22	Naph	2	N(CH ₂) ₄ CH ₂ OH	CH ₂	71	10.5±1 μM
23	Naph	1	NH	CH ₂	88	34.5±2.5 μM
25	Naph	1	N(CH ₂) ₂ COOH	CH ₂	70	28.4±4.7 μM
26	Naph	1	N(CH ₂) ₂ CH ₂ OH	CH ₂	73	20.5±0.65 µM

28	Naph	1	N(CH ₂) ₃ COOH	CH ₂	44	-
29	Naph	1	N(CH ₂) ₃ CH ₂ OH	CH ₂	85	33.8±0.4 µM
31	Naph	1	N(CH ₂) ₄ COOH	CH ₂	8	-
32	Naph	1	N(CH ₂) ₄ CH ₂ OH	CH ₂	68	23.0±0.9 µM

^aEfficacy has been calculated in transactivation assay on HepG2 cells as percent of inhibition of transactivation caused by CDCA at 10 μ M, set as 100%. ^bIC₅₀ has been determined for efficacy \geq 50%. IC₅₀ values (μ M) were calculated from at least three experiments. Results are expressed as mean \pm SEM.

The efficacy of compounds **3f** and **13** on FXR was then evaluated in a cell-free SRC-1 recruitment Alpha Screen experiment. In this assay, FXR-SRC-1 recruitment is measured in presence of CDCA at 500 nM with or without different concentrations of **3f** and **13**. As reported in Figure 2A, both compounds show high efficacy in counteracting SRC-1 peptide recruitment prompted by CDCA when tested at 500 nM and 1000 nM. Afterwards, we attempted to see whether **3f** and **13** interacts with common off-targets, such as the nuclear receptors liver X receptor α and β (LXR α and β), the peroxisome proliferator-activated receptor γ (PPAR γ) and pregnane X receptor (PXR) (Figure 2B-2C). Compounds **3f** and **13** showed no agonistic and antagonistic effects toward any of these receptors.



Figure 2. A) The effect of **3f** and **13** at 500 nM and 1000 nM in antagonizing SRC-1 recruitment on FXR by CDCA at 500 nM. Each measurement has been repeated in triplicate and SD < 5%; B-C) Off-target activity. B) HepG2 cells were stimulated with GW3965 (GW, 10 μ M) or Rosiglitazone (ROSI, 500 nM), or Rifaximin (RIF, 10 μ M) as positive controls and compounds **3f** and **13** (10 μ M); C) Cells were stimulated with 5 μ M of compounds **3f** and **13** in combination with the relative positive control. Results are expressed as mean \pm SEM. *p < 0.05 versus not treated cells (NT).

In order to evaluate the physicochemical parameters of the abovementioned analogs, LC-MS analysis were assessed (Table 2). Both compounds exhibited good aqueous solubility offering also the possibility to improve their solubility and polarity by a salt formation via the amine group. Instead, large differences were observed in their metabolic stability, as resulted by *in vitro* incubation with rat liver microsomes. Compound **13** showed a very low metabolic stability *in vitro*, with only 9.4% of unmodified molecule remaining after 40 min, and these data rule out its pharmacological potential.

Table 2. In vitro	pharmacokinetics for	compounds 3f and 13
-------------------	----------------------	---------------------

Compound	Solubility ^a (µM)	logD	Cl _{int} ^b	$t_{\frac{1}{2}}(\min)$	% [°]
3f	200	0.34	20.67	111.8	76.2
13	110.4	0.58	201	11.5	9.4

^aAqueous solubility at pH 7.4; ^bReported as μ L/min/mg protein; ^ePercentage of compound remaining in solution after 40 min incubation. Each measurement has been repeated in triplicate and SD < 5%.

Collectively, compound **3f** combines the high potency/efficacy in antagonizing FXR (Table 1) with excellent metabolic stability (about 76% remaining after 40 min of *in vitro* incubation, Table 2), thus representing a new promising chemotype of FXR antagonist. Furthermore, we tested also its behavior in the parallel artificial membrane permeability assay (PAMPA), to measure its effective permeability (express as logPe) through an artificial lipid membrane.¹⁷ Propanolol and furosemide at 250 μ M were used as positive and negative control molecules giving a logPe of -4.875 for propanolol and of -6.503 for furosemide. In this assay, **3f** displayed an average propensity to cross the membrane *in vitro* (logPe -5.046).

To gain insights into the antagonism of compound **3f**, we then investigated the downstream genes of FXR by real-time PCR (Figure 3). The HepG2 (1×10^6) were plated and, after 24 hours of starvation, were stimulated with CDCA (10 μ M) and compound **3f** at 0.1 and 1 μ M concentration.



Figure 3. Compound **3f** modulates FXR target genes. Real-time PCR analysis of mRNA expression on FXR target genes in HepG2 cells primed with CDCA (10 μ M) alone or in combination with increasing concentrations of **3f** (0.1 and 1 μ M), or with vehicle

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36 37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

(DMSO) alone. Values are normalized to GAPDH. The relative mRNA expression is analyzed according to the CT method. Data were calculated from at least three experiments. Results are expressed as actual mean between the two concentrations \pm SEM *p < 0.05 versus not treated cells (NT); # p<0.05 versus CDCA stimulated cells.

As shown in Figure 3, CDCA induced the expression of SHP, OSTα, PEPCK, GC6P whereas decrease CYP7A1 relative mRNA expression and **3f** reverts the effect of CDCA on the above FXR targeted genes. These results demonstrate that compound **3f** is a potent, effective and selective FXR antagonist.

In order to elucidate the binding mode of the newly synthesized FXR antagonists, we performed docking calculations, which is a widely used computational technique to generate and rank ligand/protein complexes based on empirical scoring functions.¹⁸⁻²⁰

In particular, we performed molecular docking calculations on the most potent derivatives **3f** and **13** (Figure 4) in the crystal structure of the FXR-ligand binding domain (LBD) in the antagonist conformation (PDB code: 4OIV).²¹



Figure 4. Docking pose of (A) **3f** (cyan sticks) and (B) **13** (yellow sticks) in the crystal structure of the FXR-LBD (PDB code: 40IV).²¹ FXR is shown as grey cartoons, with amino acids important for ligand binding depicted as sticks. Non-polar hydrogens are omitted for clarity. Hydrogen bonds are shown as dashed black lines.

We note that the structure of the FXR-LBD in this conformation is rather different if compared with that of the FXR-LBD in the agonist form. In particular, in the agonist state the ligand binding site is defined by helices 3, 5, 6, 7, 11, and 12, with the latter forming the recognition site for the coactivator peptides.²² At variance with the agonist form, in the antagonist state the hydrophobic C-terminal part of H11 is bended filling part of the ligand binding pocket and sending H12 to the binding site of the coactivators peptides of the other FXR monomer. This conformational change blocks the receptor in a not activable state.²¹ Docking of **3f** and **13** (lowest energy conformation, Figure 4) in the FXR-LBD antagonist conformation shows that the ligand oxadiazole ring engages both a water-mediated hydrogen bond and a T-shape interaction with the side chain of His451 on H11. Additionally, the naphtyl ring of **3f** and **13** establishes a number of hydrophobic contacts with residues such as Ala295, Val299, Leu455, and Met456. On the other side, the piperidine ring of **3f** and **13** can establish favorable interactions with Ile356 and Ile361, and might form water-mediated hydrogen bonds with Ser336 and Tyr373. The overlap in the FXR-LBD of the binding mode of **3f** and **13** with that of the FXR co-crystallized antagonist *N*-benzyl-*N*-(3-(*tert*-butyl)-4-hydroxyphenyl)-2,6-dichloro-4-

(dimethylamino) benzamide (NDB) shows that the ligands occupy similarly the ligand binding site, although NDB can form additional interactions with the receptor though its 3-(*tert*-butyl)-4-hydroxyphenyl moiety (Figure S1). Interestingly, additional docking calculations on 9 show that also the binding mode of this compound is superimposable to that of NBD (Figure S2). This finding explains why compounds endowed with an alcoholic side chain on the piperidine nucleus (i.e. 9, 19, 22 and 26) have FXR antagonistic profile.

In conclusion, we report the discovery of a new chemotype of FXR antagonists, featuring a central oxadiazole ring with a protonable piperidine nucleus at C-5 and a naphtyl group at C-3. We note that the piperidine moiety plays a different role in our compounds if compared with the compounds reported by Teno et al.¹³ In particular, in the Teno's compounds the piperidine works as a spacer to place the H-bond acceptor group (the carbonyl CO) in the proper position to interact with His298, while in our compounds the piperidine is not acetylated and therefore available as H-bond donor group in the FXR-LBD. Furthermore, the presence of a free piperidine makes our compounds basic with the piperidine protonated and an overall net charge equals to +1.

Our study identified compounds **3f** and **13** as potent and selective FXR antagonists. The ability in reverting the effect of CDCA on the expression of several FXR targeted genes combined with the excellent pharmacokinetic properties makes compound **3f** the most promising lead identified in this study and suitable for further development.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website.

Experimental procedures, docking poses of 3f and 13 with the crystallographic pose of NBD at the FXR-LBD; ¹H NMR of compounds 3a-3f and 4-32 (PDF).

AUTHOR INFORMATION

Corresponding Author

*Prof. Simona De Marino; e-mail: sidemari@unina.it

Notes

The authors declare no competing financial interest

Funding Sources

This work was supported by University of Naples Federico II "Finanziamento della Ricerca in Ateneo (DR/2016/341, February 2016)", by MIUR-ITALY PRIN2015 "Top-down and Bottom-up approach in the development of new bioactive chemical entities inspired on natural products scaffolds" (Project N. 2015MSCKCE_003) and by the Swiss National Science Foundation (Project N. 200021_163281).

ACKNOWLEDGMENTS

V.L. also thanks the COST action CA15135 (Multi-target paradigm for innovative ligand identification in the drug discovery process MuTaLig) for the support.

ABBREVIATIONS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

37

38

39

59

60

AF-2, activation function 2 (domain); Boc, tert-butyloxycarbonyl; CDCA, chenodeoxycholic acid; Clint, intrinsic clearance; CYP7A1, alpha-hydroxylase; cholesterol 7 DIPEA. N.Ndiisopropylethylamine; DMF, N,N-dimethylformamide; 6-ECDCA, 6-ethyl chenodeoxycholic acid; FXR-LBD, Farnesoid X Receptor-Ligand Binding Domain; HBTU, N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate; NAFLD, non-alcoholic fatty liver disease; GC6P, glucose-6-phosphatase; NDB, N-benzyl-N-(3-(tert-butyl)-4-hydroxyphenyl)-2,6-dichloro-4-(dimethylamino) benzamide; OSTα, organic solute transporter alpha; PAMPA, parallel artificial membrane permeability assay; PCR, polymerase chain reaction; PDB, protein data bank; PEPCK, phosphoenolpyruvate carboxykinase; SHP, small heterodimer partner; SRC-1, steroid receptor coactivator-1; TFA, trifluoroacetic acid.

REFERENCES

 Forman, B. M.; Goode, E.; Chen, J.; Oro, A. E.; Bradley, D. J.; Perlmann, T.; Noonan, D. J.; Burka, L. T.; McMorris, T.; Lamph, W. W.; Evans, R. M.; Weinberger, C. Identification of a nuclear receptor that is activated by farnesol metabolites. *Cell* **1995**, *81*, 687-693.

Makishima, M.; Okamoto, A. Y.; Repa, J. J.; Tu, H.; Learned, R. M.; Luk, A.; Hull, M. V.; Lustig, K. D.; Mangelsdorf, D. J.; Shan, B. Identification of a nuclear receptor for bile acids. *Science* 1999, 284, 1362-1365.

(3) Parks, D. J.; Blanchard, S. G.; Bledsoe, R. K.; Chandra, G.; Consler, T. G.; Kliewer, S. A.; Stimmel, J. B; Willson, T. M.; Zavacki, A. M.; Moore, D. D.; Lehmann, J. M. Bile acids: natural ligands for an orphan nuclear receptor. *Science* **1999**, *284*, 1365-1368.

orphan nuclear receptor. *Science* 1999, 284, 1365-1368.
Zhang, Y.; Lee, F. Y.; Barrera, G.; Lee, H.; Vales, C.; Gonzalez, F. J.; Willson, T. M.; Edwards, P. A. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. *Proc. Natl. Acad. Sci. USA* 2006, 103, 1006-1011.

- (5) Claudel, T.; Staels, B.; Kuipers, F. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. *Arterioscler. Thromb. Vasc. Biol.* 2005, 25, 2020-2030.
 (6) Cincipal St. Managerlä, A. D. Bilding, C. F. Europei, S. F. XB.
 - (6) Cipriani, S.; Mencarelli, A.; Palladino, G.; Fiorucci, S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. *J. Lipid Res.* **2010**, *51*, 771-784.
- (7) Brzozowski, A. M.; Pike, A. C.; Dauter, Z.; Hubbard, R. E.; Bonn, T.; Engström, O.; Ohman, L.; Greene, G. L.; Gustafsson, J. A.; Carlquist, M. Molecular basis of agonism and antagonism in theoestrogen receptor. *Nature* 1997, *389*, 753-758.
- (8) Prawitt, J.; Caron, S.; Staels, B. How to modulate FXR activity to treat the metabolic syndrome. *Drug Discov. Today Dis. Mech.* 2009, 6, e55-e64.
 (0) Continue De Staele, D. EXP. a mericipal treat for the metabolic.
- (9) Cariou, B.; Staels, B. FXR: a promising target for the metabolic syndrome? *Trends Pharmacol. Sci.* 2007, *28*, 236-243.
- 47 (10) Sepe, V.; Distrutti, E.; Fiorucci, S.; Zampella, A. Farnesoid X
 48 receptor modulators 2014-present: a patent review. *Expert Opin. Ther.*49 *Pat.* 2018, 28, 351-364.
 (11) State Control of the St
- (11) Stedman, C.; Liddle, C.; Coulter, S.; Sonoda, J.; Alvarez, J. G.;
 Evans, R. M.; Downes, M. Benefit of farnesoid X receptor inhibition in obstructive cholestasis. *Proc. Natl. Acad. Sci. USA* 2006, *103*, 11323-11328.
- 53 (12) Xu, Y. Recent progress on bile acid receptor modulators for treatment of metabolic diseases. J. Med. Chem. 2016, 59, 6553-6579.
 (12) Tang, N. Vamachita, Y. Janaki, Y. Fujimori, K. Jana, M. K. Kanaki, K. Janaki, K. Ja
- (13) Teno, N.; Yamashita, Y.; Iguchi, Y.; Fujimori, K.; Une, M.;
 Nishimaki-Mogami, T.; Hiramoto, T.; Gohda, K. Nonacidic
- 56 Chemotype Possessing N-Acylated Piperidine Moiety as Potent
- 57 Farnesoid X Receptor (FXR) Antagonists. ACS Med. Chem. Lett. 2018, 9, 78-83.
 58 (1) Sobreidt, L. Sobierle, S., Collrich, L., Keiser, A., Mark, D.
 - (14) Schmidt, J.; Schierle, S.; Gellrich, L.; Kaiser, A.; Merk, D.
 - Structural optimization and in vitro profiling of N-phenylbenzamide-ACS Paragon Plus Environment

based farnesoid X receptor antagonists. *Bioorg. Med. Chem.* 2018, 26, 4240-4253.

(15) Gonzalez, F. J.; Jiang, C.; Patterson, A. D. An intestinal microbiota-farnesoid X receptor axis modulates metabolic disease. *Gastroenterology* **2016**, *151*, 845-59.

(16) Flesch, D.; Gabler, M.; Lill, A.; Carrasco Gomez, R.; Steri, R.; Schneider, G.; Stark, H.; Schubert-Zsilavecz, M.; Merk, D. Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties. *Bioorg. Med. Chem.* **2015**, *23*, 3490-3498.

(17) Miele, E.; Valente, S.; Alfano, V.; Silvano, M.; Mellini, P.; Borovika, D.; Marrocco, B.; Po, A.; Besharat, Z.; Catanzaro, G.; Battaglia, G.; Abballe, L.; Zwergel, C.; Stazi, G.; Milite, C.; Castellano, S.; Tafani, M.; Trapencieris, P.; Mai, A.; Ferretti, E.; The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells. *Oncotarget.* **2017**, *40*, 68557-68570.

(18) Anzini, M.; Braile, C.; Valenti, S.; Cappelli, A.; Vomero, S.; Marinelli, L.; Limongelli, V.; Novellino, E.; Betti, L.; Giannaccini, G.; Lucacchini, A.; Ghelardini, C.; Norcini, M.; Makovec, F.; Giorgi G.; Ian Fryer, R. Ethyl 8-Fluoro-6-(3-nitrophenyl)-4H-imidazo[1,5a][1,4]benzodiazepine-3-carboxylate as novel, highly potent, and safe antianxiety agent. J. Med. Chem. **2008**, *51*, 4730-4743.

(19) Famiglini, V.; La Regina, G.; Coluccia, A.; Pelliccia, S.; Brancale, A.; Maga, G.; Crespan, E.; Badia, R.; Riveira-Muñoz, E.; Esté, J. A.; Ferretti, R.; Cirilli, R.; Zamperini, C.; Botta, M.; Schols, D.; Limongelli, V.; Agostino, B.; Novellino, E.; Silvestri, R. Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors. *J. Med. Chem.* **2014**, *57*, 9945-9957.

(20) Nuti, E.; Casalini, F.; Avramova, S. I.; Santamaria, S.; Fabbi, M.; Ferrini, S.; Marinelli, L.; La Pietra, V.; Limongelli, V.; Novellino, E.; Cercignani, G.; Orlandini, E.; Nencetti, S.; Rossello, A. Potent arylsulfonamide inhibitors of tumor necrosis factor- α converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models. *J. Med. Chem.* **2010**, *53*, 2622-2635.

(21) Xu, X.; Xu, X.; Liu, P.; Zhu, Z. Y.; Chen, J.; Fu, H. A.; Chen, L. L.; Hu, L. H.; Shen, X. Structural basis for small molecule NDB (*N*-Benzyl-*N*-(3-(tert-butyl)-4-hydroxyphenyl)-2,6-dichloro-4-

(dimethylamino) benzamide) as a selective antagonist of farnesoid X receptor α (FXR α) in stabilizing the homodimerization of the receptor *J. Biol. Chem.* **2015**, *290*, 19888-19899.

(22) Mi, L. Z.; Devarakonda, S.; Harp, J. M.; Han, Q.; Pellicciari, R.; Willson, T. M.; Khorasanizadeh, S.; Rastinejad, F. Structural basis for bile acid binding and activation of the nuclear receptor FXR. *Mol. Cell* **2003**, *11*, 1093-1100.







44x23mm (300 x 300 DPI)